explore -WSS

explore

author：focus 2025-09-29 20:51:33 - browse：8187

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Who gets to use the title 'doctor'?

WSS

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Lindsay Lohan welcomes 1st child with husband Bader Shammas

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Resistance to cancer drugs: A new genetic explanation

Argenx drug significantly slows progression of nerve disorder

'Reaching a detente': STAT's Helen Branswell on covering Covid

entertainment

explore

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Novavax promises a turnaround & Lilly roils the obesity market

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Drug repurposing or repositioning? The language matters

How dance can help health care workers heal from trauma

Malaria cases in Florida and Texas: Here’s what you need to know

New warning issued for rebooking air travel after delays, cancellations

Novavax promises a turnaround & Lilly roils the obesity market

Woman gored by Bison at Yellowstone

focus

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Why some people catch Covid but never get sick

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Congress likely to miss an opportunity to fix drug shortages issue

Europe sees delivery challenges ahead on Alzheimer's therapies

leisure time

hotspot

entertainment

Wikipedia